phr
Bluelighter
PURDUE PHARMA L.P. RECEIVES FDA APPROVAL FOR BUTRANS™ (buprenorphine) TRANSDERMAL SYSTEM CIII
Purude Pharma
7.1.10
Stamford, CT – July 1st, 2010 – Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days. Purdue expects to launch Butrans commercially in the U.S. early in 2011.
...
Link!
Purude Pharma
7.1.10
Stamford, CT – July 1st, 2010 – Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days. Purdue expects to launch Butrans commercially in the U.S. early in 2011.
...
Link!
